Criticism of misguided Chu et al. article
Chu, Brhlikova and Pollock's article suggests the WHO rethink its decision to include misoprostol on the Essential Medicines List. Their paper is a sad example of workers in an elite setting advocating policies with the potential to endanger the lives of thousands of vulnerable women in low-resource settings.
The self-administration of misoprostol, or use by traditional birth attendants, is the most immediate and practical solution to help the least developed countries move towards achieving Millennium Development Goal 5. 1 It is true that in some studies oxytocin performs marginally better than misoprostol, 2 but as mentioned by Chu et al., oxytocin administration is not currently feasible in most low-resource settings. Misoprostol presents an opportunity to achieve some semblance of health equity. 3 The paper is also methodologically and ethically flawed. It reviews the 172 published papers on the use of misoprostol to control postpartum haemorrhage (PPH) in the framework of high-quality obstetric services and it explicitly omits studies that are not randomized controlled trials (RCTs). However, RCTs are often impossible to conduct in most low-resource settings where maternal death rates are highest. The paper by Prata et al 4 . included in the review, in fact, was not an RCT. In the case of misoprostol, an undisputed powerful uterotonic, the most practical RCT would compare misoprostol to a placebo, since the reality in low-resource settings leaves only these two options. Consequently, a RCT would randomly allocate the risk of death to women in the control arm when we know that misoprostol might have the potential to save their lives.
Since Chu et al. conducted their review; a RCT in Belgaum India found 400 μg sublingual misoprostol to be more effective than 10 IU intramuscular oxytocin, as measured by blood loss (mean blood loss 192 ± 124 mL with misoprostol and 366 ± 136 mL blood loss with oxytocin). 5 These data, together with compelling literature from non-RCTs in low-resource settings, strongly endorse the WHO's decision, which weighed all of the evidence, with considerations of the larger context and implications. A reversal of their decision would only hurt the very women that Chu et al. purport to be helping. Rethinking WHO Guidance I write due to concern that persons who wish to restrict misoprostol use, because of personal biases against termination of pregnancy, might attempt to use the article by Chu, Brhlikova, and Pollock to influence policy. The safety and efficacy of misoprostol has been demonstrated in hospital settings, and does not merit debate.
The authors review only four studies of misoprostol use in community and home births. Studies of community and home births are difficult, comparison with placebo is deemed unethical by many, and blinding of misoprostol use is essentially impossible due to the shivering. The one study, by Hoj, which utilized a placebo found a significant difference in severe blood loss, the outcome (other than death) which is most critical. The authors attempt to discredit studies due to exclusion of high risk patients. The exclusion criteria listed for the Mobeen study include planning not to deliver at the birth center, previous Cesarean section, and 'unlikely to deliver vaginally', conditions which would appropriately and ethically mandate referral for hospital delivery. The excluded women would be at increased risk of uterine rupture, which is not primarily treated with uterotonics. They note that Mobeen's study shows that PPH rates in both groups decreased as the study progressed, and hypothesized this was due to later-recruited midwives being more skilled. This supports the use of misoprostol by less-skilled birth attendants, rather than not using it at all, if one wants to decrease PPH.
Oxytocin alone does not always work, whether for induction of labor or prevention or treatment of hemorrhage. Those of us who attend births in the developed world often use misoprostol in addition to oxytocin. I would hate to have misoprostol withdrawn from my pharmacopeia in the USA. The issue is not whether WHO should keep misoprostol on the essential drug list, but rather who should be allowed access to misoprostol, which is an issue that each nation should decide, depending on its own national needs and priorities.
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The publication of the epidemiologically and statistically ill-informed article and analysis presented in 'Rethinking WHO guidance: review of evidence for misoprostol use in the prevention of postpartum haemorrhage' 1 is troublesome. While various criticisms may be and have been made of the Cochran review 2 there is no excuse for the lack of awareness of the methodologically stringent review and meta-analysis, 3 which clearly demonstrates that methodologically sound studies find a substantial and highly significant benefit in the provision of misoprostol for postpartum haemorrhage prevention. The authors superficially discuss study quality while ignoring the valid implications thereof in their analysis and interpretation. The criteria by which causal associations are made, of which, statistical significance is but one criterion, particularly the existence of at least one or more methodologically sound studies, the consistency of direction across studies, biological plausibility, temporality, etc. are also critical. While simple presentation of sound studies have been presented that permits valid inference, 4 this article criticizes then includes methodologically questionable information and misconstrues the implications of sound studies, to challenge the more accurate and more sophisticated analyses of the evidence which WHO has correctly used for its inclusion of misoprostol in its recommendations. Rethinking WHO guidance on misoprostol use in the prevention of postpartum heamorrhage: authors' respon se
Pathfinder takes exception to our methods but provides a false account of our analysis nor does it say how or why the use of the PRISM instrument would have come to a different conclusion. Pathfinder notes that the WHO decision was based on 21 and not 4 studies as argued in our paper. This is true for overall safety and efficacy profile of misoprostol. However, the sections directly relevant to community settings are based on 4 RCTs. WHO unedited report states that with respect to the prevention of PPH 'The application provided the results from 4 RCTs (278, 279, 280, 281) to support the use of misoprostol for the prevention of PPH in settings where injectable uterotonics are not available or feasible to use'. 2 Pathfinder criticizes us for not conducting a meta-analysis however the heterogenous nature of the studies meant this was not possible. Pathfinder might note that the Cochrane systematic review could not conduct a meta-analysis of community trials and comes to the same conclusion 'all four recent trials have design and setting differences that make the summing up of their results difficult.' 3 We identified randomized controlled trials of misoprostol in community and home setting from academic databases and systematic reviews and meta-analyses; our methods critically appraised study design, intervention and outcomes of these studies (see method section).
The recently published Cochrane Systematic Review 'Prostaglandins for preventing postpartum haemorrhage' 3 looked at a total of 72 trials (52,678 women) conducted in low-, middle-and high-income countries included 68 trials conducted in hospitals and performed by skilled caregivers and four community studies. Our search of academic databases identified the same 4 RCTs, the same four studies discussed in the WHO unedited report.
According to the Cochrane review of the four studies, the Guinea-Bissau trial showed that almost half the women in the trial experienced higher than usual blood loss while the Gambia trial was inadequately powered. Derman's own study, the India 2006c trial, was deemed more applicable to community settings where the 'expectant' management of the third stage of labour is the norm. Although the results of this study were significant (RR 0.20; 95% CI 0.04 to 0.91, 2/812 versus 10/ 808), Cochrane reviewers do not discuss the weakening of the association by the observation of temporal trends in the intervention and control arms (suggesting effects from factors other than misoprostol) nor do they mention the lack of generalisability because the RCT excluded women with or at high risk of complications.
None of the responses to our paper engage with the science and significantly all overlook the absence of generalizability of findings. They ignore the fact that, even where tests are significant, if the study excludes all or most women with pregnancy complications or trials include antenatal screening and other services that are not available to women outside the trial, the applicability and generalizability of the study findings are seriously limited.
In this respect, Derman's response to our review is curious not least given his earlier acknowledgement of the lack of generalizability of the findings of his own study 4 and the existence of temporal trends 5 , two criteria which he lists as important for causal associations.
As Kerr and Potts note conducting trials in community setting is difficult but the same standards of evidence apply and reviews of evidence and recommendations based on these must not use difficulties in
